# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cartesian Therapeutics reported Phase 2b trial results for Descartes-08 in generalized myasthenia gravis, showing significant i...
Pursuant to the terms of the securities purchase agreement, the Company is selling an aggregate of 3,563,247 shares of its comm...
Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 ob...
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.
Oppenheimer analyst Matthew Biegler reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $50 pric...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $54...
Oppenheimer analyst Matthew Biegler maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $50 price...
Oppenheimer analyst Matthew Biegler initiates coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform rating and ...